Dr. Duncan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
NIH Clinical Center
Bethesda, MD 20892
Summary
- Dr. Brynn Duncan is a pediatric hematologist/oncologist in Bethesda, MD specializing in CAR T cell therapy for hematologic malignancies. She received her medical degree from Georgetown University School of Medicine and completed her residency in pediatrics at the University of Virginia. She completed her fellowship in pediatric hematology and oncology at Johns Hopkins and the National Cancer Institute. She has 8 publications and over 150 citings.
Education & Training
National Heart, Lung, and Blood InstituteAdvanced Clinical Fellow, 2023 - 2024
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2019 - 2023
University of Virginia Medical CenterResidency, Pediatrics, 2016 - 2019
Georgetown University School of MedicineClass of 2016- Gettysburg CollegeBS, Biology, Magna cum laude
Certifications & Licensure
MD State Medical License 2019 - 2026
VA State Medical License 2016 - 2019- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Chief Fellow Johns Hopkins/NCI, 2021-2022
Clinical Trials
- Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag Start of enrollment: 2020 Dec 01
- Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia Start of enrollment: 2023 Jul 25
Publications & Presentations
PubMed
- 39 citationsVal-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine TumorsMeghaan P. Walsh, Brynn B. Duncan, Shannon M. Larabee, Aviva C. Krauss, Jessica P. E. Davis
Plos One. 2013-03-12 - 19 citationsMurine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor.Haiying Qin, Kazusa Ishii, Sang M. Nguyen, Paul Su, Chad R. Burk
Blood. 2018-11-01 - 25 citationsApplying a clinical lens to animal models of CAR-T cell therapies.Brynn B Duncan, Cynthia E Dunbar, Kazusa Ishii
Molecular Therapy. Methods & Clinical Development. 2022-12-08
Research History
- Clinical FellowUnder the mentorship of Dr. Cynthia Dunbar in the NHLBI, Dr. Duncan generated CAR constructs incorporating the sodium iodide symporter to study CAR-T cell trafficking via PET imaging in xenograft and syngeneic nonhuman primate models. She was an Associate Investigator for two DBA clinical trials.2020 - 2024
- Postbaccalaureate Cancer Research Training AwardUnder the mentorship of Dr. Terry Fry in the NCI, Dr. Duncan worked with immunocompetent murine models of rhabdomyosarcoma to study the effects of immunomodulatory small molecules in combination with adoptive cell therapies. She also began her work with CAR-T cells in the Fry lab.2010 - 2012
Professional Memberships
- Member
- Society of Hematologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
